Patent Granted in Israel for RECCE Anti-Infectives
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has announced the granting of a new patent in Israel for its anti-infectives, specifically for the preparation of biologically active copolymers. This marks the first patent granted to Recce in Israel, with additional patent submissions currently under review.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Recce Receives AUD $11.17m R&D Advance
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- RCE Establishes Strategic Partnership in South-East Asia
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
Later from Recce Pharmaceuticals
- Recce Pharmaceuticals - Business Update
- Recce Completes 5,000 R327 Doses Per Week under GMP
- Safety Committee Approves High Dose of 4,000mg
- China Patent Granted for RECCE Anti-Infectives
- MCRI Pilot Study- Positive Efficacy Data for Lung Infections
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals